“As a leader in the industry, it was important for us to not only find a solution that would help us meet our long-term patient safety initiatives as a company, but also pave the way for addiction treatment providers at large,” said American Addiction Centers’ CEO, Michael Cartwright. “Detox is such a critical point in a patient’s recovery journey, but it is often met with unforeseen clinical challenges.”
EarlySense is an FDA-cleared patient monitoring system that uses sensors to continuously track the patient’s heart rate, breathing patterns and movements. When it identifies irregular heart beats or breathing patterns and sudden movements, among other concerning changes, EarlySense immediately distributes real-time alerts to a central nursing hub, tablets and mobile devices.
One of AAC’s Southern California facilities, Laguna Treatment Hospital, has already launched EarlySense.
“On multiple occasions, EarlySense has detected abnormal vital signs while the patient was resting in bed identifying various diagnosis such as pneumonia, respiratory distress and countless others,” said Mertis Shearry, BSN, RN, director of nursing at Laguna Treatment Hospital. “Patients and loved ones can be certain that with the help of this technology, nursing staff are ready to provide early medical interventions if needed.”
Editor’s Note: This article was updated May 10, 2018 at 7:50 a.m. A previous verison of this article incorrectly stated EarlySense was FDA-approved, however, it is FDA-cleared.
More articles on artificial intelligence:
Intermedix named one of America’s best midsize employers by Forbes
AMA funnels $27.2M into value-based care startup incubator
Blockchain collaborative Hyperledger adds 2 healthcare members
